Viking Therapeutics (NASDAQ:VKTX – Get Free Report) issued its earnings results on Wednesday. The biotechnology company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.06, Briefing.com reports. During the same period in the prior year, the firm earned ($0.19) earnings per share.
Viking Therapeutics Trading Up 4.0 %
Shares of VKTX traded up $2.58 on Friday, reaching $67.26. 6,204,842 shares of the company’s stock were exchanged, compared to its average volume of 4,829,201. The stock has a market capitalization of $7.42 billion, a P/E ratio of -73.41 and a beta of 1.03. The business has a 50 day moving average price of $55.75 and a two-hundred day moving average price of $55.89. Viking Therapeutics has a 12 month low of $8.28 and a 12 month high of $99.41.
Insider Activity at Viking Therapeutics
In other news, CFO Greg Zante sold 66,756 shares of the business’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $74.69, for a total transaction of $4,986,005.64. Following the completion of the transaction, the chief financial officer now directly owns 174,854 shares in the company, valued at approximately $13,059,845.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, CFO Greg Zante sold 66,756 shares of the business’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $74.69, for a total value of $4,986,005.64. Following the completion of the transaction, the chief financial officer now owns 174,854 shares of the company’s stock, valued at approximately $13,059,845.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Marianna Mancini sold 281,425 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $78.66, for a total value of $22,136,890.50. Following the sale, the chief operating officer now directly owns 348,508 shares in the company, valued at approximately $27,413,639.28. The disclosure for this sale can be found here. 4.70% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
Get Our Latest Stock Analysis on VKTX
Viking Therapeutics Company Profile
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Read More
- Five stocks we like better than Viking Therapeutics
- Stock Dividend Cuts Happen Are You Ready?
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- What Investors Need to Know to Beat the Market
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- What is a buyback in stocks? A comprehensive guide for investors
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.